Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL10588716 | 0.99 | MAOA (0.34) | MAOAMAOB | |
| SCHEMBL9680591 | 0.87 | TRPA1 (0.32) | TRPA1 | |
| Arginine SCHEMBL6240955 | 0.78 | OTC (0.32) | — | |
| SCHEMBL7210084 | 0.77 | — | — | |
| SCHEMBL9032487 | 0.73 | MAOA (0.31) | MAOAMAOB | |
| SCHEMBL6780552 | 0.73 | TRPA1 (0.35) | TRPA1 | |
| SCHEMBL11724902 | 0.73 | SRD5A2 (0.34) | — | |
| SCHEMBL11202182 | 0.73 | NOTUM (0.39) | — | |
| Hydrochloric Acid SCHEMBL9223535 | 0.72 | PARP1 (0.31) | MAOAMAOB | |
| Hydrochloric Acid SCHEMBL10432400 | 0.72 | NOTUM (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3344262-A1 | IMMUNE CELLS HAVING INCREASED IMMUNITY OR RESISTANCE TO AN IMMUNOSUPPRESSIVE CYTOKINE AND USE OF THE SAME | Innate Tumor Immunity, Inc. (US) | 2018-07-11 | — | — | EP | claimed |
| WO-2017040670-A1 | IMMUNE CELLS HAVING INCREASED IMMUNITY OR RESISTANCE TO AN IMMUNOSUPPRESSIVE CYTOKINE AND USE OF THE SAME | IFM THERAPEUTICS, INC (US) | 2017-03-09 | — | — | WO | claimed |
| US-20170056448-A1 | IMMUNE CELLS HAVING INCREASED IMMUNITY OR RESISTANCE TO AN IMMUNOSUPPRESSIVE CYTOKINE AND USE OF THE SAME | IFM THERAPEUTICS, INC (US) | 2017-03-02 | — | — | US | claimed |
| EP-0203795-B1 | Benzo [i,j] quinolizine-2-carboxylic acid derivatives, the salts and their hydrates, pharmaceutical compositions thereof, and process for preparing the same | TOKYO TANABE COMPANY LIMITED (JP) | 1992-07-29 | — | — | EP | claimed |
| US-4720495-A | Benzo[ij]quinolizine-2-carboxylic acids useful for treating bacterial infection | TOKYO TANABE CO. LIMITED (JP) | 1988-01-19 | — | — | US | claimed |
| EP-0203795-A2 | Benzo [i,j] quinolizine-2-carboxylic acid derivatives, the salts and their hydrates, pharmaceutical compositions thereof, and process for preparing the same | TOKYO TANABE COMPANY LIMITED (JP) | 1986-12-03 | — | — | EP | claimed |
| JP-56055389-A | — | — | None | — | — | JP | disclosed |
| JP-63192753-A | — | — | None | — | — | JP | disclosed |
| JP-55118485-A | — | — | None | — | — | JP | disclosed |
| JP-57193459-A | — | — | None | — | — | JP | disclosed |
| EP-3922279-A1 | DRUG DELIVERY COMPOSITIONS AND USES THEREOF | Dana Farber Cancer Institute, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| US-20210246211-A1 | DRUG DELIVERY COMPOSITIONS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-08-12 | — | — | US | disclosed |
| US-11021539-B2 | Drug delivery compositions and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-4443447-A | Phenyl-substituted tricyclic antibacterial agents | RIKER LABORATORIES, INC. (US) | 1984-04-17 | — | — | US | disclosed |
| US-4404207-A | Antimicrobial 8-substituted benzo [IJ]quinolizines | RIKER LABORATORIES, INC. (US) | 1983-09-13 | — | — | US | disclosed |
| JP-S57193459-A | QUINOLINE DERIVATIVE | OTSUKA PHARMACEUT CO LTD | 1982-11-27 | — | — | JP | disclosed |
| JP-S5655389-A | BENZO IJ QUINOLIDINE-2-CARBOXYLIC ACID DERIVATIVE, AND ITS PREPARATION | OTSUKA PHARMACEUT CO LTD | 1981-05-15 | — | — | JP | disclosed |
| JP-S55118485-A | BENZO IJ QUINOLIZINE-2-CARBOXYLIC ACID DERIVATIVE | OTSUKA PHARMACEUT CO LTD | 1980-09-11 | — | — | JP | disclosed |
| US-4014877-A | MICROBIOCIDES | RIKER LABORATORIES, INC. (US) | 1977-03-29 | — | — | US | disclosed |
| US-3985882-A | ADMISTERING | RIKER LABORATORIES, INC. (US) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170056448-A1 | IMMUNE CELLS HAVING INCREASED IMMUNITY OR RESISTANCE TO AN IMMUNOSUPPRESSIVE CYTOKINE AND USE OF THE SAME | IL2, IFNG, IL2RA | MAOA 4789/4885MAOB 4818/4885TRPA1 4740/4885 |
| US-20210246211-A1 | DRUG DELIVERY COMPOSITIONS AND USES THEREOF | STING1, IL15, IL15RA | MAOA 3782/4885MAOB 4477/4885TRPA1 2840/4885 |
| US-11021539-B2 | Drug delivery compositions and uses thereof | STING1, IL15, IL15RA | MAOA 3782/4885MAOB 4477/4885TRPA1 2840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.